Obstructive Sleep Apnea May Raise Risk for Sudden Death
Meta-analysis shows sleep apnea linked to increased risk for sudden death, cardiovascular mortality
Cardiology
Udenafil Under Review for Single Ventricle Heart Disease
The NDA submission is supported by data from more than 200 studies completed over the last 2 decades, including the pivotal phase 3 FUEL trial.
Gene Therapy Gets Orphan Drug Status for Genetic Hypertrophic Cardiomyopathy
TN-201 is a potentially curative, one-time, AAV-based gene therapy to address genetic hypertrophic cardiomyopathy caused by MYBPC3 gene mutations.
Weight Loss Supplement Recalled Due to Presence of Stimulant
DMAA constricts blood vessels and arteries, leading to increased blood pressure and cardiovascular problems.
FDA: Consumer Electronics May Impact Implanted Medical Devices
The FDA is advising patients with implanted medical devices to consider keeping consumer electronics at least 6 inches away from the implanted medical device.
Mavacamten Under Review for Obstructive Hypertrophic Cardiomyopathy
Mavacamten is an oral, selective allosteric inhibitor of cardiac myosin.
Arcalyst Approved for Recurrent Pericarditis
Arcalyst is a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1.
Study Reveals Previously Unknown Drug-Associated Arrhythmias
To identify medications with potential proarrhythmic association.
Verquvo Approved for Heart Failure with Reduced Ejection Fraction
The approval was based on data from the double-blind, placebo-controlled phase 3 VICTORIA trial.
Dapagliflozin Under Review for Chronic Kidney Disease
The FDA has granted Priority Review to dapagliflozin (Farxiga) for the treatment of new or worsening CKD.
